Involvement of trace elements in the pathogenesis of prion diseases

Current Pharmaceutical Biotechnology

Volumn 15, Issue 11, 2014, Pages 1049-1057

  Mizuno, Dai ^a   Koyama, Hironari ^b   Ohkawara, Susumu ^b   Sadakane, Yutaka ^c   Kawahara, Masahiro ^a  

^a MUSASHINO UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^c SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Amyloid; Calcium homeostasis; Combinaconformational disease; Synapse

Indexed keywords

AMPA RECEPTOR; AMYLOID BETA PROTEIN; BINDING PROTEIN; CARBOXYFLUORESCEIN; CARNOSINE; PRION PROTEIN; REACTIVE OXYGEN METABOLITE; TRACE ELEMENT; ZINC TRANSPORTER; NEUROPROTECTIVE AGENT; PRION; PROTEIN BINDING;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; CALCIUM HOMEOSTASIS; CONFORMATIONAL TRANSITION; COPPER BINDING; HUMAN; IRON BINDING; MANGANESE BINDING; MEMBRANE DAMAGE; METAL BINDING; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRION DISEASE; PROTEOMICS; ZINC BINDING; ANIMAL; CHEMISTRY; METABOLISM; PRION; PRION DISEASES; PROTEIN CONFORMATION;

ANIMALS; CARNOSINE; HUMANS; NEUROPROTECTIVE AGENTS; PRION DISEASES; PRIONS; PROTEIN BINDING; PROTEIN CONFORMATION; TRACE ELEMENTS;

EID: 84925875143     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666141103020625     Document Type: Article

References (93)

1. Prusiner, S.B. Prion diseases and the BSE crisis. Science, 1997, 278, 245-251.
2. Brundin, P.; Melki, R.; Kopito, R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol., 2010, 11, 301-307.
3. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. USA, 1998, 95, 13363-13383.
4. Carrell R.W.; Lomas, D.A. Conformational disease. Lancet, 1997, 350, 134-138.
5. Kawahara, M. Role of calcium dyshomeostasis via amyloid channels in the pathogenesis of Alzheimer's disease. Curr. Pharmaceut. Design, 2010, 16, 2779-2789.
6. Mizuno, D; Kawahara, M. Oligomerization of proteins and neurodegenerative diseases. In Oligomerization (ed by Lesieur, C.); InTech, 2014.
7. Brown, D.R. Brain proteins that mind metals: A neurodegenerative perspective. Dalton Trans., 2009, 21, 4069-4076.
8. Winklhofer, K.F.; Tatzelt, J.; Haass, C. The two faces of protein misfolding: gain-and loss-of-function in neurodegenerative diseases. EMBO J., 2008, 27, 336-49.
9. Vassallo, N.; Herms, J. Cellular prion protein function in copper homeostasis and redox signalling at the synapse. J. Neurochem., 2003, 86(3), 538-44.
10. Simoneau, S.; Rezaei, H.; Sales, N.; Kaiser-Schulz, G.; Lefebvre-Roque, M.; Vidal, C.; Fournier, J.G.; Comte, J.; Wopfner, F.; Grosclaude, J.; Schatzl, H.; Lasmezas, C.I. In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog., 2007, 3(8), e125.
11. Fioriti, L.; Angeretti, N.; Colombo, L.; De Luigi, A.; Colombo, A.; Manzoni, C.; Morbin, M.; Tagliavini, F.; Salmona, M.; Chiesa, R.; Forloni, G. Neurotoxic and gliotrophic activity of a synthetic peptide homologous to Gerstmann-Straussler-Scheinker disease amyloid protein. J. Neurosci., 2007, 27(7), 1576-1583.
12. Bolognin, S.; Messori, L.; Zatta, P. Metal ion physiopathology in neurodegenerative disorders. Neuromolecular Med., 2009, 11, 223-238.
13. Hodak, M.; Bernholc, J. Insights into prion protein function from atomistic simulations. Prion, 2010, 4, 13-9.
14. Brown, D.R.; Qin, K.; Herms, J.W.; Madlung, A.; Manson, J.; Strome, R.; Fraser, P.E.; Kruck, T.; von Bohlen, A.; Schulz-Schaeffer, W.; Giese, A.; Westaway, D.; Kretzschmar, H. The cellular prion protein binds copper in vivo. Nature, 1997, 390, 684-687.
15. Jackson, G.S.; Murray, I.; Hosszu, L.L.; Gibbs, N.; Waltho, J.P.; Clarke, A.R.; Collinge, J. Location and properties of metal-binding sites on the human prion protein. Proc. Natl. Acad. Sci. USA, 2001, 98(15), 8531-5.
16. Brown, D.R.; Besinger, A. Prion protein expression and superoxide dismutase activity. Biochem. J., 1998, 334, 423-429.
17. Stys, P.K.; You, H.; Zamponi, G.W. Copper-dependent regulation of NMDA receptors by cellular prion protein: implications for neurodegenerative disorders. J. Physiol., 2012, 590, 1357-1368.
18. Varela-Nallar, L.; Toledo, E.M.; Larrondo, L.F.; Cabral, A.L.; Martins, V.R.; Inestrosa, N.C. Induction of cellular prion protein gene expression by copper in neurons. Am. J. Physiol. Cell Physiol., 2006, 290(1), C271-281.
19. Brown, D.R.; Harris, D.A. Copper and zinc cause delivery of the prion protein from the plasma membrane to a subset of early endosomes and the Golgi. J. Neurochem., 2003, 87, 353-363.
20. White, A.R.; Collins, S.J.; Maher, F.; Jobling, M.F.; Stewart, L.R.; Thyer, J.M.; Beyreuther, K.; Masters, C.L.; Cappai, R. Prion protein-deficient neurons reveal lower glutathione reductase activity and increased susceptibility to hydrogen peroxide toxicity. Am. J. Pathol., 1999, 155(5), 1723-1730.
21. Frederickson, C.J.; Bush, A.I. Synaptically released zinc: physiological functions and pathological effects. Biometals. Int. J. Role Metal Ions Biol., Biochem., Med., 2001, 14, 353-366.
22. Kawahara, M.; Mizuno, D.; Koyama, H.; Konoha, K.; Ohkawara, S.; Sadakane, Y. Disruption of zinc homeostasis and the pathogenesis of senile dementia. Metallomics, 2013, 6, 209-212.
23. Stellato, F.; Spevacek, A.; Proux, O.; Minicozzi, V.; Millhauser, G.; Morante, S. Zinc modulates copper coordination mode in prion protein octa-repeat subdomains. Eur. Biophys. J., 2011, 40(11), 1259-1270.
24. Schmitt-Ulms, G.; Ehsani, S.; Watts, J.C.; Westaway, D.; Wille, H. Evolutionary descent of prion genes from the ZIP family of metal ion transporters. PLoS One, 2009, 4(9), e7208.
25. Ehsani, S.; Tao, R.; Pocanschi, C.L.; Ren, H.; Harrison, P.M.; Schmitt-Ulms, G. Evidence for retrogene origins of the prion gene family. PLoS One, 2011, 6(10), e26800.
26. Fukada, T.; Kambe, T. Molecular and genetic features of zinc transporters in physiology and pathogenesis. Metallomics, 2011, 3(7), 662-674.
27. Pocanschi, C.L.; Ehsani, S.; Mehrabian, M.; Wille, H.; Reginold, W.; Trimble, W.S.; Wang, H.; Yee, A.; Arrowsmith, C.H.; Bozoky, Z.; Kay, L.E.; Forman-Kay, J.D.; Rini, J.M.; Schmitt-Ulms, G. The ZIP5 ectodomain co-localizes with PrP and may acquire a PrP-like fold that assembles into a dimer. PLoS One, 2013, 8(9), e72446.
28. Watt, N.T.; Griffiths, H.H.; Hooper, N.M. Neuronal zinc regulation and the prion protein. Prion, 2013, 7(3), 203-238.
29. Watt, N.T.; Taylor, D.R.; Kerrigan, T.L.; Griffiths, H.H.; Rushworth, J.V.; Whitehouse, I.J.; Hooper, N.M. Prion protein facilitates uptake of zinc into neuronal cells. Nat. Commun., 2012, 3, 1134.
30. Rachidi, W.; Chimienti, F.; Aouffen, M.; Senator, A.; Guiraud, P.; Seve, M.; Favier, A. Prion protein protects against zinc-mediated cytotoxicity by modifying intracellular exchangeable zinc and inducing metallothionein expression. J. Trace Elem. Med. Biol., 2009, 23(3), 214-223.
31. Johnson, C.J.; Gilbert, P.U.; Abrecht, M.; Baldwin, K.L.; Russell, R.E.; Pedersen, J.A.; Aiken, J.M.; McKenzie, D. Low copper and high manganese levels in prion protein plaques. Viruses, 2013, 5(2), 654-662.
32. Thackray, A.M.; Madec, J.Y.; Wong, E.; Morgan-Warren, R.; Brown, D.R.; Baron, T.; Bujdoso, R. Detection of bovine spongiform encephalopathy, ovine scrapie prion-related protein (PrPSc) and normal PrPc by monoclonal antibodies raised to copperrefolded prion protein. Biochem. J., 2003, 370, 81-90.
33. Davies, P.; Brown, D.R. Manganese enhances prion protein survival in model soils and increases prion infectivity to cells. PLoS One, 2009, 4(10), e7518.
34. White, S.N.; O'Rourke, K.I.; Gidlewski, T.; Ver Cauteren, K.C.; Mousel, M.R.; Phillips, G.E.; Spraker, T.R. Increased risk of chronic wasting disease in Rocky Mountain elk associated with decreased magnesium and increased manganese in brain tissue. Can. J. Vet. Res., 2010, 74(1), 50-53.
35. Slivarichova, D.; Mitrova, E.; Ursinyova, M.; Uhnakova, I.; Koscova, S.; Wsolova, L. Geographic accumulation of Creutzfeldt-Jakob disease in Slovakia--environmental metal imbalance as a possible cofactor. Cent. Eur. J. Public Health, 2011, 19(3), 158-164.
36. Singh, A.; Mohan, M.L.; Isaac, A.O.; Luo, X.; Petrak, J.; Vyoral, D.; Singh, N. Prion protein modulates cellular iron uptake: A novel function with implications for prion disease pathogenesis. PLoS One, 2009, 4(2), e4468.
37. Singh, A.; Haldar, S.; Horback, K.; Tom, C.; Zhou, L.; Meyerson, H.; Singh, N. Prion protein regulates iron transport by functioning as a ferrireductase. J. Alzheimers Dis., 2013, 35(3), 541-552.
38. Singh, A.; Kong, Q.; Luo, X.; Petersen, R.B.; Meyerson, H.; Singh, N. Prion protein (PrP) knock-out mice show altered iron metabolism: a functional role for PrP in iron uptake and transport. PLoS One, 2009, 4(7), e6115.
39. Singh, A.; Qing, L.; Kong, Q.; Singh, N. Change in the characteristics of ferritin induces iron imbalance in prion disease affected brains. Neurobiol. Dis., 2012, 45(3), 930-938.
40. Singh, A.; Beveridge, A.J.; Singh, N. Decreased CSF transferrin in sCJD: a potential pre-mortem diagnostic test for prion disorders. PLoS One, 2011, 6(3), e16804.
41. Kawahara, M.; Negishi-Kato, M.; Sadakane, Y. Calcium dyshomeostasis and neurotoxicity of Alzheimer's beta-amyloid protein. Expert Rev. Neurother., 2009, 9, 681-693.
42. Bush, A.I.; Tanzi, R.E. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics, 2008, 5(3), 421-432.
43. Kawahara, M.; Muramoto, K.; Kobayashi, K.; Mori, H.; Kuroda, Y. Aluminum promotes the aggregation of Alzheimer's amyroid s-protein in vitro. Biochem. Biophys. Res. Commun., 1994, 198, 531-535.
44. Kawahara, M.; Kato, M.; Kuroda, Y. Effects of aluminum on the neurotoxicity of primary cultured neurons and on the aggregation of s-amyloid protein. Brain Res. Bull., 2001, 55, 211-217.
45. Bush, A.I.; Pettingell, W.H.; Multhaup, G.; d Paradis, M.; Vonsattel, J.P.; Gusella, J.F.; Beyreuther, K.; Masters, C.L.; Tanzi, R.E. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science, 1994, 265(5177), 1464-1467.
46. Atwood, C.S.; Moir, R.D.; Huang, X.; Scarpa, R.C.; Bacarra, N.M.; Romano, D.M.; Hartshorn, M.A.; Tanzi, R.E.; Bush, A.I. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem., 1998, 273(21), 12817-12826.
47. Uversky, V.N.; Li, J.; Fink, A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem., 2001, 276(47), 44284-44296.
48. Mirhashemi, S.M.; Shahabaddin, M.E. Evaluation of aluminium, manganese, copper and selenium effects on human islets amyloid polypeptide hormone aggregation. Pak. J. Biol. Sci., 2011, 14(4), 288-292.
49. Bonetto, V.; Massignan, T.; Chiesa, R.; Morbin, M.; Mazzoleni, G.; Diomede, L.; Angeretti, N.; Colombo, L.; Forloni, G.; Tagliavini, F.; Salmona, M. Synthetic miniprion PrP106. J. Biol. Chem., 2002, 277(35), 31327-31334.
50. Forloni, G.; Angeretti, N.; Chiesa, R.; Monzani, E.; Salmona, M.; Bugiani, O.; Tagliavini, F. Neurotoxicity of a prion protein fragment. Nature, 1993, 362(6420), 543-546.
51. De Gioia, L.; Selvaggini, C.; Ghibaudi, E.; Diomede, L.; Bugiani, O.; Forloni, G.; Tagliavini, F.; Salmona, M. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J. Biol. Chem., 1994, 269(11), 7859-7862.
52. Grasso, D.; Milardi, D.; La Rosa, C.; Rizzarelli, E. The different role of Cu++ and Zn++ ions in affecting the interaction of prion peptide PrP106-126 with model membranes. Chem. Commun. (Camb), 2004, 21(2), 246-247.
53. Kawahara, M.; Koyama, H.; Nagata, T.; Sadakane, Y. Zinc, copper, and carnosine attenuate neurotoxicity of prion fragment PrP106-126. Metallomics, 2011, 3, 726-734.
54. Inayathullah, M.; Satheeshkumar, K.S.; Malkovskiy, A.V.; Carre, A.L.; Sivanesan, S.; Hardesty, J.O.; Rajadas, J. Solvent microenvironments and copper binding alters the conformation and toxicity of a prion fragment. PLoS One, 2013, 8(12), e85160.
55. Thakur, A.K.; Srivastava, A.K.; Srinivas, V.; Chary, K.V.; Rao, C.M. Copper alters aggregation behavior of prion protein and induces novel interactions between its N-and C-terminal regions. J. Biol. Chem., 2011, 286(44), 38533-38545.
56. Ward, B.; Walker, K.; Exley, C. Copper(II) inhibits the formation of amylin amyloid in vitro. J. Inorg. Biochem., 2008, 102(2), 371-375.
57. Lu, Y.; Liu, A.; Zhou, X.; Kouadir, M.; Zhao, W.; Zhang, S.; Yin, X.; Yang, L.; Zhao, D. Prion peptide PrP106-126 induces inducible nitric oxide synthase and proinflammatory cytokine gene expression through the activation of NF-κB in macrophage cells. DNA Cell Biol., 2012, 31(5), 833-838.
58. Fernaeus, S.; Land, T. Increased iron-induced oxidative stress and toxicity in scrapie-infected neuroblastoma cells. Neurosci. Lett., 2005, 382(3), 217-220.
59. Wang, S.B.; Shi, Q.; Xu, Y.; Xie, W.L.; Zhang, J.; Tian, C.; Guo, Y.; Wang, K.; Zhang, B.Y.; Chen, C.; Gao, C.; Dong, X.P. Protein disulfide isomerase regulates endoplasmic reticulum stress and the apoptotic process during prion infection and PrP mutant-induced cytotoxicity. PLoS One, 2012, 7(6), e38221.
60. Verkhratsky, A. Calcium and cell death. Subcell. Biochem., 2007, 45, 465-480.
61. Arispe, N.; Rojas, E.; Pollard, H.B. Alzheimer disease amyloid sprotein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. USA, 1993, 90, 567-571.
62. Arispe, N.; Pollard, H.B.; Rojas, E. Zn2+ interactions with Alzheimer's amyloid s protein calcium channels. Proc. Natl. Acad. Sci. USA, 1996, 93, 1710-1715.
63. Kagan, B.L.; Jang, H.; Capone, R.; Teran Arce, F.; Ramachandran, S.; Lal, R.; Nussinov, R. Antimicrobial properties of amyloid peptides. Mol. Pharm., 2012, 9(4), 708-717.
64. Soscia, S.J.; Kirby, J.E.; Washicosky, K.J.; Tucker, S.M.; Ingelsson, M.; Hyman, B.; Burton, M.A.; Goldstein, L.E.; Duong, S.; Tanzi, R.E.; Moir, R.D. The Alzheimer's disease-associated amyloid betaprotein is an antimicrobial peptide. PLoS One, 2010, 5(3), e9505.
65. Lin, M.C.; Mirzabekov,T; Kagan, B.L. Channel formation by a neurotoxic prion protein fragment. J. Biol. Chem., 1997, 272, 44-47.
66. Bahadi, R.; Farrelly, P.V.; Kenna, B.L.; Curtain, C.C.; Masters, C.L.; Cappai, R.; Barnham, K.J.; Kourie, J.I. Cu2+-induced modification of the kinetics of Aβ(1-42) channels. Am. J. Physiol. Cell Physiol., 2003, 285(4), C873-880.
67. Farrelly, P.V.; Kenna, B.L.; Laohachai, K.L.; Bahadi, R.; Salmona, M.; Forloni, G.; Kourie, J.I. Quinacrine blocks PrP (106-126)-formed channels. J. Neurosci. Res., 2003, 74(6), 934-41.
68. Paulis, D.; Maras, B.; Schinina, M.E.; di Francesco, L.; Principe, S.; Galeno, R.; Abdel-Haq, H.; Cardone, F.; Florio, T.; Pocchiari, M.; Mazzanti, M. The pathological prion protein forms ionic conductance in lipid bilayer. Neurochem. Int., 2011, 59(2), 168-174.
69. Solomon, I.H.; Biasini, E.; Harris, D.A. Ion channels induced by the prion protein: mediators of neurotoxicity. Prion, 2012, 6, 40-5.
70. Pasupuleti, M.; Roupe, M.; Rydengard, V.; Surewicz, K.; Surewicz, W.K.; Chalupka, A.; Malmsten, M.; Sorensen, O.E.; Schmidtchen, A. Antimicrobial activity of human prion protein is mediated by its N-terminal region. PLoS One, 2009, 4(10), e7358.
71. Kawahara, M.; Arispe, N.; Kuroda, Y.; Rojas, E. Alzheimer's disease amyloid s-protein forms Zn2+-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. Biophys. J., 1997, 73, 67-75.
72. Kawahara, M.; Arispe, N.; Rojas, E.; Kuroda, Y. Alzheimer's samyloid, human islet amylin and prion protein fragment evoke intracellular free-calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell-line. J. Biol. Chem., 2000, 275, 14077-14083.
73. Kawahara. M.; Ohtsuka, I.; Yokoyama, S.; Kato-Negishi, M.; Sadakane, Y. Membrane incorporation, channel formation, and disruption of calcium homeostasis by Alzheimer's s-amyloid protein, Int. J. Alzheimer Dis., 2011, 304583.
74. Lal, R., Lin, H.; Quist, A.P. Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. Biochim. Biophys. Acta, 2007, 1768(8), 1966-75.
75. Lashuel, H.A.; Hartley, D.; Petre, B.M.; Walz, T.; Lansbury, P.T. Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature, 2002, 418(6895), 291.
76. Stys, P.K.; You, H.; Zamponi, G.W. Copper-dependent regulation of NMDA receptors by cellular prion protein: implications for neurodegenerative disorders. J Physiol., 2012, 590, 1357-1368.
77. Sabo, S.L.; Ikin, A.F.; Buxbaum, J.D.; Greengard, P. The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo. J. Neurosci., 2003, 23, 5407-5415.
78. Kay, A.R. Imaging synaptic zinc: promises and perils. Trends in Neurosci., 2006, 29, 200-206.
79. Duce, J.A.; Tsatsanis, A.; Cater, M.A.; James, S.A.; Robb, E.; Wikhe, K.; Leong, S.L.; Perez, K.; Johanssen, T.; Greenough, M.A.; Cho, H.H.; Galatis, D.; Moir, R.D.; Masters, C.L.; McLean, C.; Tanzi, R.E.; Cappai, R.; Barnham, K.J.; Ciccotosto, G.D.; Rogers, J.T.; Bush, A.I. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell, 2010, 142, 857-867.
80. Mizuno, D.; Kawahara, M. The molecular mechanism of zinc neurotoxicity and the pathogenesis of vascular type dementia. Intern. J. Mol. Sci., 2013, 14(11), 22067-81.
81. Sindreu, C.; Bayes, A.; Altafaj, X.; Perez-Clausell, J. Zinc transporter-1 concentrates at the postsynaptic density of hippocampal synapses. Mol. Brain, 2014, 7, 7-16.
82. Griffiths, H.H.; Whitehouse, I.J.; Hooper, N.M. Regulation of amyloid-β production by the prion protein. Prion, 2012, 6(3), 217-222.
83. Fluharty, B.R.; Biasini, E.; Stravalaci, M.; Sclip, A.; Diomede, L.; Balducci, C.; La Vitola, P.; Messa, M.; Colombo, L.; Forloni, G.; Borsello, T.; Gobbi, M.; Harris, D.A. An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J. Biol. Chem., 2013, 288(11), 7857-7866.
84. Faux, N.G.; Ritchie, C.W.; Gunn, A.; Rembach, A.; Tsatsanis, A.; Bedo, J.; Harrison, J.; Lannfelt, L.; Blennow, K.; Zetterberg, H.; Ingelsson, M.; Masters, C.L.; Tanzi, R.E.; Cummings, J.L.; Herd, C.M.; Bush, A.I. PBT2 rapidly improves cognition in Alzheimer's Disease: Additional phase II analyses. J. Alzheimers Dis., 2010, 20(2), 509-16.
85. Bareggi, S.R.; Braida, D.; Pollera, C.; Bondiolotti, G.; Formentin, E.; Puricelli, M.; Poli, G.; Ponti, W.; Sala, M. Effects of clioquinol on memory impairment and the neurochemical modifications induced by scrapie infection in golden hamsters. Brain Res., 2009, 1280, 195-200.
86. Sigurdsson, E.M.; Brown, D.R.; Alim, M.A.; Scholtzova, H.; Carp, R.; Meeker, H.C.; Prelli, F.; Frangione, B.; Wisniewski, T. Copper chelation delays the onset of prion disease. J. Biol. Chem., 2003, 278(47), 46199-46202.
87. Soto, C.; Kascsak, R.J.; Saborio, G.P.; Aucouturier, P.; Wisniewski, T.; Prelli, F.; Kascsak, R.; Mendez, E.; Harris, D.A.; Ironside, J.; Tagliavini, F.; Carp, R.I.; Frangione, B. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet, 2000, 355(9199), 192-197.
88. Hipkiss, A.R. Carnosine and its possible roles in nutrition and health. Adv. Food Nutr. Res., 2009, 57, 87-154.
89. Mizuno, D.; Kawahara, M. Carnosine: A possible drug for vascular dementia. J. Vasc. Med. Surg., 2014, 2, doi:10.4172/2329-6925. 1000146.
90. Corona, C.; Frazzini, V.; Silvestri, E.; Lattanzio, R.; La Sorda, R.; Piantelli, M.; Canzoniero, L.M.; Ciavardelli, D.; Rizzarelli, E.; Sensi, S.L. Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice. PLoS One, 2011, 6(3), e17971.
91. Kawahara, M.; Konoha, K.; Nagata, T.; Sadakane, Y. Protective substances against zinc-induced neuronal death after ischemia: Carnosine a target for drug of vascular type of dementia. Rec. Pat. CNS Drug Discov., 2007, 2, 145-149.
92. Koyama, H.; Konoha, K.; Sadakane, Y.; Ohkawara, S.; Kawahara, M. Zinc neurotoxicity and the pathogenesis of vascular-type dementia: Involvement of calcium dyshomeostasis and carnosine. J. Clin. Toxicol., 2012, 3-2.
93. Kawahara, M.; Konoha, K.; Nagata, A.; Sadakane, Y. Food and drink for prevention or treatment of cerebrovascular dementia, its package or container and agent for prevention or treatment of cerebrovascular dementia. JP 5382633, 2013.